Cyclacel Pharmaceuticals Q1 EPS $(2.27) Beats $(4.74) Estimate, Sales $29.00K
Cyclacel Pharmaceuticals Q1 EPS $(2.27) Beats $(4.74) Estimate, Sales $29.00K
Cyclacel Pharmicals第一季度每股收益美元（2.27美元）超过预期（4.74美元），销售额为29.00万美元
Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported quarterly losses of $(2.27) per share which beat the analyst consensus estimate of $(4.74) by 52.11 percent. This is a 67.8 percent increase over losses of $(7.05) per share from the same period last year. The company reported $29.00 thousand in sales this quarter.
Cyclacel Pharmicals（纳斯达克股票代码：CYCC）公布的季度亏损为每股2.27美元，比分析师普遍预期的4.74美元（4.74美元）高出52.11％。这比去年同期每股亏损7.05美元（7.05）增长了67.8％。该公司报告本季度销售额为29,000美元。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。